Evidence-based medicine AI platform bags $210m to help physicians make better-informed decisions by analyzing peer-reviewed literature.
AI-powered clinical decision support platform OpenEvidence has secured $210 million in Series B funding at a valuation of $3.5 billion. The company’s system synthesizes peer-reviewed literature in real time, guiding physicians toward faster, better-informed decisions grounded in the latest research – and it could have significant implications in longevity medicine.
Staggeringly, OpenEvidence claims it is already used daily by over 40% of physicians in the United States, with more than 100 million Americans being treated this year by a physician who used the tool to support clinical decision-making. The platform is designed to deliver concise, scientifically grounded answers to complex clinical questions within seconds, integrating content from institutions such as the American Medical Association and The New England Journal of Medicine to create a unified interface for medical evidence.
While OpenEvidence predominantly positions itself as a technological solution to physician burnout and data overload, it could also become part of the essential infrastructure required for next-generation fields like longevity medicine. The platform does not yet offer a dedicated longevity-specific service, but its combination of real-time, point-of-care guidance and in-depth, asynchronous research support align closely with the demands of clinicians focused on aging, healthspan and preventative care.
“Physicians are superheroes, and OpenEvidence is giving these superheroes new superpowers,” said founder Daniel Nadler, adding that his mission to build an AI copilot for clinicians is “rooted in the belief that AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve.”
Longevity medicine requires continual engagement with emerging data on molecular aging pathways, novel therapeutics and biomarker-driven treatment personalization, and OpenEvidence can help facilitate this by aggregating, curating and analyzing a vast and fast-changing body of scientific literature that includes a wealth of aging-related science.
With personalized care central to managing aging and age-related disease, clinicians require tools that can adapt to the individual health profiles of patients. A tool like OpenEvidence can provide up-to-date evaluations of therapies that may not yet be widely accepted or included in standard guidelines, and may help support clinicians developing bespoke treatment plans aimed at disease prevention and longevity optimization.
In addition, access and equity are significant factors in longevity medicine, where the gap between innovation and availability has historically been wide, and OpenEvidence can help democratize access to high-quality clinical intelligence. Its capacity to reduce the time required to evaluate new evidence enables practitioners in all environments to remain current with the accelerating pace of discovery in aging and preventive medicine.
Of course, OpenEvidence’s insights will be constrained by the quality and availability of published research, and in fields where data is sparse or inconclusive, its outputs will reflect those limitations. Nonetheless, it provides a potential framework for how longevity medicine principles could potentially be adopted at scale.
“Thus far, the digital transformation of healthcare has mostly fallen short in its efforts to deliver trusted, evidence-based clinical decision support to clinicians when they need it most,” said Dr Robert M Wachter, Chair of the Department of Medicine at UCSF. “The partnership between the American Medical Association, a cornerstone of medical research and analysis for more than a century, and OpenEvidence… represents a significant step toward fulfilling that promise.”
The latest funding round, which brings OpenEvidence’s total funding to over $300 million, was co-led by Google Ventures and Kleiner Perkins, with follow-on participation from Sequoia Capital and additional investments from Coatue, Conviction and Thrive.
“Physicians are drowning in information but starving for timely insights,” said Google Ventures’ Sangeen Zeb. “OpenEvidence changes that equation, bringing clinicians into the modern era.”
“It’s hard to imagine a better use for AI than OpenEvidence,” said Kleiner Perkins Chairman John Doerr. “Daniel Nadler and his world-class team are building what I believe will become an AI-era treasure, a life-saving resource for doctors, patients, and their families. I can’t imagine the future without it.”
